3 completed, 2 active not recruiting, 2 recruiting, 2 terminated. 6 Phase 1, 6 Phase 2, 2 Not applicable, 1 Phase 4.
Follow Subcutaneous panniculitis-like T-cell lymphoma: new trials by email Literature Review of Subcutaneous panniculitis-like T-cell lymphoma trials Research Report on Subcutaneous panniculitis-like T-cell lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| A Registry for People With T-cell Lymphoma Optional Blood Sample and Nail Sample - T-cell Lymphoma, NK-Cell Lymphoma | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2023-07-27 | 2026-05-20 | |
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas DR-01 - LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Dren Bio | 200 | 2022-07-13 | 2026-06-17 |
| Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma Brentuximab Vedotin, Pembrolizumab - Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Withdrawn | Northwestern University | 2020-03-01 | 2023-10-10 | |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration - Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma | Not applicable | Completed | Mayo Clinic | 29 | 2016-01-19 | 2019-11-15 |
| CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL CEOP/IVE/GDP chemotherapy regimen, CEOP chemotherapy regimen for 6 cycles - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma | Phase 2 | Unknown | Shandong Provincial Hospital | 106 | 2015-09-01 | 2020-03-10 |
| Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency Cholecalciferol, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma | Not applicable | Active not recruiting | Mayo Clinic | 565 | 2013-03-06 | 2026-06-16 |
| CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Cyclophosphamide 750mg/m2, Vincristine 1.4mg/m2, Doxorubicin 50mg/m2 - ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified | Phase 4 | Unknown | Ruijin Hospital | 200 | 2012-09-01 | 2017-11-14 |
| Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas Rituximab, Etoposide, Siplizumab - T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2009-01-13 | 2021-11-03 |
| Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma Vorinostat, Bortezomib - Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 1 | 2009-01-01 | 2012-08-07 |
| SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma Zolinza (vorinostat), Cyclophosphamide, Doxorubicin - Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 14 | 2008-11-01 | 2014-09-09 |
| Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Bortezomib, Everolimus - 714leukemia, Lymphoma | Phase 1 | Terminated | Brian Hill, MD, PhD | 30 | 2008-06-01 | 2015-10-28 |
Enteropathy-Associated T-Cell Lymphoma (12) · Immunoblastic Lymphadenopathy (10) · Lymphoma, T-Cell (10) · Lymphoma, Large-Cell, Anaplastic (8) · Lymphoma (6) · Lymphoma, Extranodal NK-T-Cell (5) · Leukemia, Large Granular Lymphocytic (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Primary Cutaneous Anaplastic Large Cell (3) · Lymphoma, T-Cell, Peripheral (3) · Mycosis Fungoides (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3)
Hemic and Lymphatic Diseases (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Lymphatic Diseases (13) · Lymphoproliferative Disorders (13) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Lymphoma, Non-Hodgkin (12) · Lymphadenopathy (10) · Lymphoma (7) · Hematologic Diseases (5) · Leukemia, Lymphoid (5) · Leukemia (4) · Chronic Disease (3) · Disease Attributes (3)
Cyclophosphamide (3) · Doxorubicin (3) · Prednisone (3) · Vincristine (3) · 10-propargyl-10-deazaaminopterin (2) · Bortezomib (2) · Etoposide (2) · Vorinostat (2) · pembrolizumab (2) · Azacitidine (1) · Brentuximab Vedotin (1) · Cholecalciferol (1) · Everolimus (1) · Fluorodeoxyglucose F18 (1) · Ifosfamide (1)
City of Hope Medical Center (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Brian Hill, MD, PhD (1) · Dren Bio (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Northwestern University (1) · Ruijin Hospital (1) · Shandong Provincial Hospital (1)
United States (11) · China (2) · Australia (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · South Korea (1) · Spain (1) · Taiwan (1)
Alex F Herrera (1) · Barbara Pro, MD (1) · Brian Hill, MD, PhD (1) · Christina Poh (1) · Jonathan Moreira, MD (1) · Steven Horwitz, MD (1) · Thomas E. Witzig, MD (1) · Thomas Witzig (1) · Wan-Jen Hong, MD (1) · Wyndham H Wilson, M.D. (1) · Xin Wang, PhD (1) · Yasuhiro Oki, MD (1)
P30CA015083 (1), P30CA033572 (1), P30CA043703 (1), P30CA060553 (1), P50CA097274 (1)